Guideline summary: Use of epoetin and darbepoetin in patients with cancer - 2007 American Society of Clinical Oncology/American Society of Hematology Clinical Practice guideline update

Journal of Oncology Practice

Volumn 4, Issue 1, 2008, Pages 48-52

  Rizzo, Douglas ^a   Somerfield, Mark R ^a   Hagerty, Karen L ^a   Seidenfeld, Jerome ^a   Bohlius, Julia ^a   Bennet, Charles L ^a   Cella, David F ^a   Djullbegovic, Benjamin ^a   Goode, Matthew ^a   Jakubowski, Ann A ^a   Rarick, Mark U ^a   Regan, David H ^a   Lichtin, Alan E ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; DOXORUBICIN; HEMOGLOBIN; IRON; LENALIDOMIDE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; THALIDOMIDE;

ANEMIA; ARTICLE; BLOOD TRANSFUSION; CANCER SURVIVAL; CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; FOOD AND DRUG ADMINISTRATION; HEMATOLOGIC MALIGNANCY; HEMOGLOBIN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; IRON BLOOD LEVEL; LOW DRUG DOSE; MEDICAL SOCIETY; MULTIPLE MYELOMA; PRACTICE GUIDELINE; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION; STATISTICAL SIGNIFICANCE; THROMBOEMBOLISM; TREATMENT RESPONSE; UNITED STATES;

EID: 42649109758     PISSN: 15547477     EISSN: None     Source Type: Journal    
DOI: 10.1200/JOP.0818502     Document Type: Article

References (2)